Multipurpose Prevention Technologies: Strategy recommendations to guide the most promising products from the lab to hands of women
Recent results from long-acting HIV prevention trials in parallel with the MPTs in the pipeline herald an exciting time for the MPT field. However, given finite resources and technical challenges to advance products from preclinical through clinical evaluation, objective benchmark criteria would be useful to identify and guide the most promising pre-clinical MPT candidates through the pipeline. This presentation at the HIVR4P 2021 Conference describes MPTs in development and a strategy for bridging funding and development gaps.
January 2021
Click for full info +Multipurpose Prevention Technologies: Strategy recommendations to guide the most promising products from the lab to hands of women
January, 2021 Recent results from long-acting HIV prevention trials in parallel with the MPTs in the pipeline herald an exciting time for the MPT field. However, given finite resources and technical challenges to advance products from preclinical through clinical evaluation, objective benchmark criteria would be useful to identify and guide the most promising pre-clinical MPT candidates through the pipeline. This presentation at the HIVR4P 2021 Conference describes MPTs in development and a strategy for bridging funding and development gaps. |
Full Info:
Resource Type:
Authors: Bethany Young Holt, Susanna Moore, Anke Hemmerling, Kavita Nanda, Greg Kopf, Thesla Palanee-Phillips, Sharon L. Achilles
Health Risks(s):
- HIV
- STI / STD
- Unintended Pregnancy
Product type(s):
- MPTs
Topic(s):
- MPTs
- Development
Region(s)
- Global